Frequency of non-V600 BRAF mutations
Mutatations in BRAF at codons other than V600 (non-V600) have been identified in 2.79% of all tissue samples in the cBIO repository, a biorepository that includes 69 next generation sequencing studies across 23 histologic subtypes of cancer [8, 9]. These widely vary across cancer types, for example, in melanoma, approximately 5% of tumors harbor these mutations. These alterations are present in 1-3% of lung adenocarcinomas, and 1% or less of ovarian carcinomas, gastric carcinomas, prostate cancer, lung squamous cell carcinomas, glioblastomas,
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.